Startup · $5.5m raised
Brisbane, QLD
Every investor coverage indicates participated in a round ResApp raised.
| Investor | Rounds | Invested |
|---|---|---|
| Fidelity International | Unnamed stage | - |
The transaction that ended ResApp's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Pfizer | Acquisition | 26 Sep 2022 | $179m | sharecafe.com.au, Techboard, Startup Daily (Mon 3 Oct 2022), Startup News (WA), Startup Daily (Wed 28 Sep 2022), SmartCompany, @AuManufacturing |
Companies ResApp acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Tony Keating | Chief Executive (former) | sharecafe.com.au, SmartCompany |
Stories naming ResApp. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
UQ medtech spin-out Ceretas sold its IPO, raising about $8 million, and now targets a fast-tracked ASX debut; the article also recalls ResApp's 2022 acquisition by Pfizer.
Also kalkine.com.au·Dealroom
Techboard's September 2022 roundup reports Australian raises led by Morse Micro's $140m Series B, several acquisitions including ResApp Health to Pfizer, fund closes by Telstra Ventures, OIF and Main Sequence, and open raises.
Ignition Lane's weekly tech roundup covering fresh Australian startup raises, new venture funds and closes, a wave of acquisitions, delistings and a liquidation, executive moves, and Canva's product launch.
Also Centerstone Capital portfolio·Startup Daily·SmartCompany·6clicks.com·ARN (ARNnet)·Centerstone Capital portfolio·Techboard·Startup Daily
Pfizer has completed its takeover of ASX-listed telehealth diagnostics company ResApp Health for $179 million, with the article recalling the company's 2015 listing, earlier raises and a Gates Foundation grant.
Pfizer has completed its purchase of Brisbane digital health company ResApp Health for $179 million, doubling its per-share offer after an April bid for the ASX-listed cough-diagnosis startup.
Also SmartCompany·Startup Daily·Startup Daily·Techboard·Startup News (WA)·sharecafe.com.au
Pfizer has bid $100m for ResApp, a Brisbane healthtech firm whose app diagnoses respiratory conditions from coughs; its board backs the deal, and the piece recalls a 2021 $5.5m raise under Fidelity International's lead.
Also Startup Daily